No Data
No Data
We Think That There Are More Issues For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Than Just Sluggish Earnings
The subdued market reaction suggests that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) recent earnings didn't contain any surprises. Our analysis suggests that along w
Pharma Tesco (300937.SZ): Net profit of 9.225 million yuan in the first quarter decreased by 70.84% year-on-year
On April 24, Gelonghui (300937.SZ) released its first quarter report. Operating revenue was 1,237 billion yuan, up 10.29% year on year, net profit was 92.25,500 yuan, down 70.84% year on year. After deducting non-net profit of 6.09 million yuan, down 80.65% year on year, with basic earnings of 0.0964 yuan per share.
Pharma Tesco (300937.SZ): Net profit for 2023 increased by 41.69% to 595.32 million yuan, and plans to pay 10.2.2 yuan
On April 9, Ge Longhui (300937.SZ) announced its 2023 annual report. During the reporting period, the company achieved operating income of 4.430 billion yuan, up 11.62% year on year; net profit attributable to shareholders of listed companies was 595.32 million yuan, up 41.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 54.271 million yuan, an increase of 37.40% year on year; basic income per share is 0.62 yuan; it plans to distribute a cash dividend of 2.20 yuan (tax included) for every 10 shares to all shareholders.
Medicago (300937.SZ): Deferred Disclosure of 2023 Annual Report
Medico-Tesco (300937.SZ) announced that the company was originally scheduled to disclose “2023...” on April 9, 2024
Medicago (300937.SZ): Termination of issuance of shares to specific targets and withdrawal of application documents
On February 23, Ge Longhui (300937.SZ) announced that the company held the 20th meeting of the 3rd board of directors and the 13th meeting of the 3rd board of supervisors on February 22, 2024 to review and pass the “Proposal on Termination of Issuance of Shares to Specific Targets and Withdrawal of Application Documents”. Since the company disclosed its plan to issue shares to specific targets, the company's board of directors, management and relevant intermediaries have been actively promoting various tasks. In view of the current complex and changing market environment and changes in external financing policies, etc., and comprehensively considering many factors such as the company's business development plan and capital operation plan, it is relevant
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) 26% Cheaper Price Remains In Tune With Revenues
The Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SZSE:300937) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareh
No Data